FindTrial
Sign In

Treatment for renal failure in chronic liver disease

To compare the efficacy of terlipressin and noradrenaline on the renal function and out come of patients with hepatorenal syndrome - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/09/002032
Enrollment
60
Registered
2011-09-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic Liver Disease Hepato renal Syndrome

Interventions

Intervention1: nor adrenaline terlipressin: max 14 days. i v route Intervention2: terlipressin: terlipressin is given in dose of 0.5 to 2 mg 6 hourly till creatine comes normal upto maximum of 14 days

Sponsors

SKIMS university
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patients with chronic liver disease and ascitis having renal failure

Exclusion criteria

Exclusion criteria: Patient with primary renal disease, patients with obstructive uropathy,hypotension,septic shock

Design outcomes

Primary

MeasureTime frame
Normalisation of renal functionsTimepoint: 14 days—

Secondary

MeasureTime frame
Survival at 30 daysTimepoint: 30 days—

Countries

India

Contacts

Public ContactDr Gul Javid

Gastroenterology

drriyazsaif@yahoo.com09419062937

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 5, 2026